Mechanistically, SMYD3 has been shown to interact and activate the HER2 receptor, estrogen receptor, VEGFR1, and SMAD3 in breast cancer cells, and it promotes cell proliferation and colony formation. Here, FLT1 is linked to breast carcinoma.